The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Arutyunov G.P.

Pirogov Russian National Research Medical University

Amelin A.V.

Pavlov First Saint Petersburg State Medical University

Voznyuk I.A.

Kulesh A.A.

Vagner Perm State Medical University

Maksimova M.Yu.

Research Center of Neurology

Mkrtchyan V.R.

Moscow Research and Clinical Center for Neuropsychiatry of the Healthcare Department

Putilina M.V.

Pirogov Russian National Research Medical University

Sorokoumov V.A.

Pavlov First Saint Petersburg State Medical University

Fonyakin A.V.

Research Center of Neurology

Khasanova D.R.

Interregional Clinical and Diagnostic Center;
Kazan State Medical University

COMPASS study results as a foundation for new treatment approach for neurological patients. Opinion of the expert council of december 18, 2021

Authors:

Arutyunov G.P., Amelin A.V., Voznyuk I.A., Kulesh A.A., Maksimova M.Yu., Mkrtchyan V.R., Putilina M.V., Sorokoumov V.A., Fonyakin A.V., Khasanova D.R.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(4): 94‑99

DOI: 10.17116/jnevro202212204194

Views: 2378

Downloaded: 117

Download PDF (RU)
Contact the author
Table of contents

COMPASS STUDY RESULTS AS A FOUNDATION FOR NEW TREATMENT APPROACH FOR NEUROLOGICAL PATIENTS. OPINION OF THE EXPERT COUNCIL OF DECEMBER 18, 2021
COMPASS STUDY RESULTS AS A FOUNDATION FOR NEW TREATMENT APPROACH FOR NEUROLOGICAL PATIENTS. OPINION OF THE EXPERT COUNCIL OF DECEMBER 18, 2021

To cite this article:

Arutyunov GP, Amelin AV, Voznyuk IA, et al. . COMPASS study results as a foundation for new treatment approach for neurological patients. Opinion of the expert council of december 18, 2021. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(4):94‑99. (In Russ.)
https://doi.org/10.17116/jnevro202212204194

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Promising approaches to the pathogenetic therapy of amyotrophic late­ral scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):13-21
Rela­pse of primary mediastinal B-cell lymphoma with isolated central nervous system invo­lvement: risk factors and search for personalized therapy. P.A. Herzen Journal of Onco­logy. 2024;(2):39-45
Hemo­dynamics and repe­rfusion in acute ischemic stroke: friends or foes?. Russian Journal of Anesthesiology and Reanimatology. 2024;(2):91-96
Analysis of stroke inci­dence seasonal changes in Bishkek. Russian Journal of Preventive Medi­cine. 2024;(4):89-96
Topi­cal application of hypo­tensive drugs for the prevention of intraocular pressure elevation after intravitreal inje­ctions of anti-VEGF drugs. Russian Annals of Ophthalmology. 2024;(2-2):73-79
Effi­cacy and Safety of Different Anti­coagulation Regi­mens for Deep Vein Thro­mbosis in Real Clinical Practice. Journal of Venous Diso­rders. 2024;(2):89-99
The impact of arti­ficial inte­lligence on double reading of mammograms. Russian Journal of Preventive Medi­cine. 2024;(5):32-37
Effi­cacy and Safety of Different Anti­coagulation Regi­mens for Deep Vein Thro­mbosis in Real Clinical Practice. Journal of Venous Diso­rders. 2024;(2):89-99
Methods of cost-effectiveness evaluation of endo­vascular patent fora­men ovale closure for seco­ndary prevention of cryptogenic stroke. Russian Journal of Preventive Medi­cine. 2024;(6):105-110
Arti­ficial inte­lligence in dermatology: oppo­rtunities and prospects. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(3):246-252

The resolution of the Council of Experts devoted to the discussion of the effectiveness of the use of a combination of rivaroxaban 2.5 mg 2 times a day and acetylsalicylic acid 100 mg per day to prevent recurrent non-coronary ischemic stroke results of the COMPASS study is presented. The advantages of this combination and the safety of its use are considered. Recommendations for the implementation of the results of the study in clinical practice are given.

Keywords:

ischemic stroke
atherothrombosis
prevention
rivaroxaban
acetylsalicylic acid
COMPASS study

Authors:

Arutyunov G.P.

Pirogov Russian National Research Medical University

Amelin A.V.

Pavlov First Saint Petersburg State Medical University

Voznyuk I.A.

Kulesh A.A.

Vagner Perm State Medical University

Maksimova M.Yu.

Research Center of Neurology

Mkrtchyan V.R.

Moscow Research and Clinical Center for Neuropsychiatry of the Healthcare Department

Putilina M.V.

Pirogov Russian National Research Medical University

Sorokoumov V.A.

Pavlov First Saint Petersburg State Medical University

Fonyakin A.V.

Research Center of Neurology

Khasanova D.R.

Interregional Clinical and Diagnostic Center;
Kazan State Medical University

Received:

17.03.2022

Accepted:

30.03.2022

List of references:

  1. World Health Organization (2021). The link is active on 22.03.22.  https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
  2. Federal’naja sluzhba gosudarstvennoj statistiki. Chislo umershih po osnovnym klassam prichin smerti. 2019 g. (In Russ.). The link is active on 22.03.22. (In Russ.). https://rosstat.gov.ru/folder/12781
  3. de Jong G, van Raak L, Kessels F, et al. Stroke subtype and mortality. a follow-up study in 998 patients with a first cerebral infarct. J Clin Epidemiol. 2003;56(3):262-268.  https://doi.org/10.1016/s0895-4356(02)00572-3
  4. Marcevich SJu, Kutishenko NP, Zagrebel’nyj AV, et al. Registr ostrogo narushenija mozgovogo krovoobrashhenija LIS-2: novye dannye po otdalennomu nabljudeniju. RFK. 2018;2:23-29. (In Russ.).
  5. Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences. Eur Heart J. 2004;25:1197-1207. https://doi.org/10.1016/j.ehj.2004.03.011
  6. Drouet L. Atherothrombosis as a Systemic Disease. Cerebrovasc Dis. 2002;13(suppl 1):1-6.  https://doi.org/10.1159/000047782
  7. Steg PG, Bhatt DL, Wilson PWF, et al. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis. JAMA. 2007;297(11):1197-1206. https://doi.org/10.1001/jama.297.11.1197
  8. Uematsu M, Nakamura T, Sugamata W, et al. Echolucency of carotid plaque is useful for assessment of residual cardiovascular risk in patients with chronic coronary artery disease who achieve LDL-C goals on statin therapy. Circ J. 2014;78(1):151-158.  https://doi.org/10.1253/circj.cj-13-0783
  9. Kwon H, Kim HK, Kwon SU, et al. Risk of major adverse cardiovascular events in subjects with asymptomatic mild carotid artery stenosis. Sci Rep. 2018;8:47-53.  https://doi.org/10.1038/s41598-018-23125-8
  10. Arbustini E, Bello B, Morbini P, et al.Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart. 1999;82(3):269-272.  https://doi.org/10.1136/hrt.82.3.269
  11. Chen YC, Huang AL, Kyaw TS, et al. Atherosclerotic Plaque Rupture. Arteriosclerosis Thromb Vasc Biol. 2016;36(8):63-72.  https://doi.org/10.1161/ATVBAHA.116.307993
  12. Cacouba PP, Abola B, Baumgartner I, et al. Cardiovascular risk factor and outcomes in peripheral artery disease in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Atherosclerosis. 2009;204(2):86-92.  https://doi.org/10.1016/j.atherosclerosis.2008.10.023
  13. Fruchart J-C, Davignon J, Hermans MP, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13:26.  https://doi.org/10.1186/1475-2840-13-26
  14. Dhindsa DS, Sandesara PB, Shapiro MD and Wong ND. The Evolving Understanding and Approach to Cardiovascular Risk Management. Front Cardiovasc Med. 2020;7:88-93.  https://doi.org/10.3389/fcvm.2020.00088
  15. Johnston S, Amarenco P. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. N Engl J Med. 2016;375:35-43.  https://doi.org/10.1056/NEJMoa1603060
  16. Benavente OR. Effects of Clopidogrel Added to Aspirinin Patients with Recent Lacunar Stroke. The SPS3 Investigators. N Engl J Med. 2012;367:817-825.  https://doi.org/10.1056/NEJMoa1204133
  17. Bath PM, Woodhouse LJ, Appleton J, et al. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. Lancet. 2018;391:850-859.  https://doi.org/10.1016/S0140-6736(17)32849-0
  18. Claiborne JS, Amarenco P, Denison H, et al. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. N Engl J Med. 2020;383:207-217.  https://doi.org/10.1056/NEJMoa1916870
  19. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack. N Engl J Med. 2013;369:11-19.  https://doi.org/10.1056/NEJMoa1215340
  20. Claiborne JS, Easton D, Farrant M. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 2018;379:215-225.  https://doi.org/10.1056/NEJMoa1800410
  21. Panchenko EP. Novye vozmozhnosti v lechenii bol’nyh so stabil’nymi projavlenijami aterotromboza. Kardiologija. 2017;57(12):82-89. (In Russ.). https://doi.org/10.18087/cardio.2017.12.10060
  22. Carcaillon L, Alhenc-Gelas M, Bejot Y, et al. Increased Thrombin Generation Is Associated With Acute Ischemic Stroke but Not With Coronary Heart Disease in the Elderly. Arterioscler Thromb Vasc Biol. 2011;31:1445-1451. https://doi.org/10.1161/ATVBAHA.111.223453
  23. Popović M, Smiljanić K, Dobutović B, et al. Thrombin and vascular inflammation. Mol Cell Biochem. 2012;359:301-313.  https://doi.org/10.1007/s11010-011-1024-x
  24. Choi BJ, Prasad A, Gulati R, et al. Coronary endothelial dysfunction in patients with early coronary artery disease is associated with the increase in intravascular lipid core plaque. Eur Heart J. 2013;34:2047-2054. https://doi.org/10.1093/eurheartj/eht132
  25. Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J. 2010;31:17-28.  https://doi.org/10.1093/eurheartj/ehp504
  26. Chan NC, Weitz JI. Antithrombotic Agents. Circ Res. 2019;124(3):426-436.  https://doi.org/10.1161/CIRCRESAHA.118.313155
  27. Eikelboom JW, Connolly SJ, Bosch J, et al.; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319-1330. https://doi.org/10.1056/NEJMoa1709118
  28. Anand S, Bosch J, Eikelboom J, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. N Engl J Med. 2017;383(21):2412-2421. https://doi.org/10.1016/S0140-6736(17)32409-1
  29. Connolly S, Eikelboom J, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;23:34-39.  https://doi.org/10.1016/S0140-6736(17)32458-3
  30. Sharma M, Hart RG, Connolly SJ, et al. Stroke Outcomes in the COMPASS Trial. Circulation. 2019;139(9):1134-1145. https://doi.org/10.1161/CIRCULATIONAHA.118.035864
  31. Eikelboom JW, Deepak L, et al. Mortality Benefit of Rivaroxaban Plus Aspirin in PatientsWith Chronic Coronary or Peripheral Artery Disease. J Am Coll Cardiol. 2021;78:14-23.  https://doi.org/10.1016/j.jacc.2021.04.083
  32. Vanassche T, Verhamme P, Anand S, et al. Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. Eur Heart J. 2021;Jun 30;pvab050. https://doi.org/10.1093/ehjcvp/pvab050
  33. Steffel J, Eikelboom JW, Anand S, et al. The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban plus Aspirin as Compared to Aspirin in Patients Chronic Vascular Disease. Circulation. 2020;142(1):40-48.  https://doi.org/10.1161/CIRCULATIONAHA.120.046048
  34. Guzik TJ, Ramasundarahettige C, Pogosova N. Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. J Am Coll Cardiol. 2021;77:511-525.  https://doi.org/10.1016/j.jacc.2020.11.061
  35. Aboyans V, Ricco JB, Bartelink MEL, et al. ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763-816.  https://doi.org/10.1093/eurheartj/ehx095
  36. Darmon A, Sorbets E, Ducrocq G, et al. Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. J Am Coll Cardio. 2019;73(25):3281-3291. https://doi.org/10.1016/j.jacc.2019.04.046
  37. Rezoljucija Evrazijskoj associacii terapevtov «Algoritm ocenki i modifikacii faktorov riska nebol’shih krovotechenij u pacientov s fibrilljaciej predserdij, poluchajushhih terapiju POAK» 2019 god. The link is active on 22.03.22. (In Russ.). https://euat.ru/upload/recommendation/1566466669.pdf
  38. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498.  https://doi.org/10.1093/eurheartj/ehaa612
  39. Klinicheskie rekomendacii «Stabil’naja ishemicheskaja bolezn’ serdca» 2020 g. The link is active on 22.03.22. (In Russ.). https://scardio.ru/content/Guidelines/2020/Clinic_rekom_IBS.pdf
  40. Nacional’nye klinicheskie rekomendacii po diagnostike i lecheniju zabo-levanij arterij nizhnih konechnostej 2019 goda. The link is active on 22.03.22. (In Russ.). https://www.angiolsurgery.org/library/recommendations/2019/recommendations_LLA_2019.pdf
  41. Klinicheskie rekomendacii «Saharnyj diabet 2 tipa u vzroslyh» 2019 goda. (In Russ.). The link is active on 22.03.22. (In Russ.). https://raeorg.ru/system/files/documents/pdf/saharnyy_diabet_2_tipa_u_vzroslyh.pdf
  42. Knuuti J, Wijns W, Saraste A, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477.  https://doi.org/10.1093/eurheartj/ehz425
  43. Frank U, Nikol S, Belch J, et al. ESVM Guideline on peripheral arterial disease. Vasa. 2019;48(suppl 102):1-79.  https://doi.org/10.1024/0301-1526/a000834
  44. Visseren FLJ, Mach F, Smulders YM, et al. ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. https://doi.org/10.1093/eurheartj/ehab484
  45. Postanovlenie Pravitel’stva RF ot 30.11.19 №1569 «O vnesenii izmenenij v gosudarstvennuju programmu Rossijskoj Federacii «Razvitie zdravoohranenija. Prilozhenie 11 «Pravila predostavlenija i raspredelenija subsidij na obespechenie profilaktiki razvitija serdechno-sosudistyh zabolevanij i serdechno-sosudistyh oslozhnenij u pacientov vysokogo riska, nahodjashhihsja na dispansernom nabljudenii, bjudzhetam sub’ektov. The link is active on 22.03.22. (In Russ.). https://base.garant.ru/73169732
  46. Prikaz Minzdrava Rossii ot 09.01.20 №1n «Ob utverzhdenii perechnja lekarstvennyh preparatov dlja medicinskogo primenenija dlja obespechenija v techenie odnogo goda v ambulatornyh uslovijah lic, kotorye perenesli ostroe narushenie mozgovogo krovoobrashhenija, infarkt miokarda, a takzhe kotorym byli vypolneny aortokoronarnoe shuntirovanie, angioplastika koronarnyh arterij so stentirovaniem i kateternaja abljacija po povodu serdechno-sosudistyh zabolevanij». The link is active on 22.03.22. (In Russ.). https://base.garant.ru/73462529

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.